Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

Neoplasm Clinical Trial

— TusaRav-QT  

Official title:

Open-label Study Evaluating the Effect of Tusamitamab Ravtansine on the QTc Interval in Participants With Metastatic Solid Tumors

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05429762
• Other study ID #: TES16382
• Secondary ID: U1111-1269-62912
• Status: Terminated
• Phase: Phase 1
• Start date: October 3, 2022
• Est. completion date: April 10, 2024

Study information

• Verified date: June 2024
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase1, single-arm study for treatment. This is a prospective multicenter, multinational, open-label study to assess the effect of tusamitamab ravtansine on the QT interval in participants with metastatic colorectal cancer (CRC), nonsquamous non small cell lung cancer (NSQ NSCLC), or gastric/ gastroesophageal junction (GEJ) adenocarcinoma for which in the judgement of the Investigator, no standard alternative therapy is available.

Description:

This is a single arm study in which participants will receive treatment with tusamitamab ravtansine until disease progression, unacceptable toxicity, the start of a new anti-cancer therapy, or the participant's or Investigator's decision to stop the treatment, whichever comes first.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 56
• Est. completion date: April 10, 2024
• Est. primary completion date: August 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of colorectal cancer (CRC) adenocarcinoma, nonsquamous non small cell lung cancer (NSQ NSCLC), or gastric/ gastroesophageal junction (GC/GEJ) adenocarcinoma, metastatic disease at study entry.

• Participants with documented disease progression, for which, in the judgment of the Investigator, no alternative medical therapy is available.

• Expression of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) will be assessed centrally using the most recent archival tumor tissue (or, if not available, a fresh biopsy sample) and at least 5 fresh-cut slides of formalin-fixed paraffin embedded (FFPE) tumor tissue sectioned. If less material is available, the participant could still be considered eligible after discussion with the Sponsor.

• Participants with CRC tumors may be assumed to have adequate CEACAM5 expression without testing results (it will be assessed retrospectively),

• Participants with NSQ NSCLC must have tumors expressing CEACAM5 or high circulating CEA if tumor tissue is not available.

• Participants with GC/GEJ must have tumors expressing CEACAM5

• Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as determined by the Investigator.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 to1.

• A female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP) and is a WOCBP and agrees to use a contraceptive method that is highly effective and for at least 7 months after the last dose of treatment. administration.

• Male participant who agrees to use effective contraception methods during and for at least 4 months after the last dose of treatment administration.

• Capable of giving signed informed consent.

Exclusion Criteria:

• Untreated brain metastases that may be considered active or leptomeningeal metastasis. A participant with asymptomatic brain metastasis/metastases is eligible.

• Significant concomitant illness

• History within the last 2 years of an invasive malignancy other than that treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.

• Any major surgery within 3 weeks prior to of first study intervention administration.

• Known uncontrolled infection with human immunodeficiency virus (HIV). Participants with a well-controlled HIV infection/disease must be on antiretroviral therapy (ART) to be eligible.

• Active infection with hepatitis A, B, or C.

• Nonresolution of any prior treatment-related toxicity .

• Unresolved corneal disorder or any previous corneal disorder.

• Use of contact lenses is not permitted.

• Prior history of Torsades de Pointes, or congenital long QT syndrome.

• Patient receives (and cannot discontinue) or is scheduled to receive a QT-prolonging drug unless if deemed necessary for the participant as per the investigators' judgment and started at least 4 weeks prior IMP administration at the same dose and the same frequency.

• QTcF interval >480 msec on screening ECG.

• Poor bone marrow, liver, kidney functions, or electrolytes values

• Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.

Related Conditions & MeSH terms

• Neoplasm

Intervention

Drug:
• Tusamitamab ravtansine
Pharmaceutical form: Concentrated solution for intravenous (IV) administration; Route of administration: IV infusion

Locations

Country	Name	City	State
Belgium	Investigational Site Number : 0560001	Edegem
France	Investigational Site Number : 2500001	Dijon
France	Investigational Site Number : 2500002	Marseille
Spain	Investigational Site Number : 7240002	Barcelona	Catalunya [Cataluña]
Spain	Investigational Site Number : 7240001	Madrid	Madrid, Comunidad De
Turkey	Investigational Site Number : 7920001	Ankara
United States	Mary Crowley Cancer Research Center Site Number : 8400002	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Belgium,  France,  Spain,  Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in QT-interval corrected (QTcF) centrally assessed		Baseline, Cycle 1, and Cycle 2 (1 Cycle = 2 weeks)
Secondary	Electrocardiogram (ECG) parameter: heart rate (HR)	To assess the effect of tusamitamab ravtansine (i.e., change from baseline) on cardiac parameters such as heart rate (HR).	Baseline, Cycle 1, and Cycle 2 (1 Cycle = 2 weeks)
Secondary	ECG parameter: QT interval	To assess the effect of tusamitamab ravtansine (i.e., change from baseline) on cardiac parameters such as QT interval.	Baseline, Cycle 1, and Cycle 2 (1 Cycle = 2 weeks)
Secondary	ECG parameter: QT interval corrected according to the Bazett's formula (QTcB)	To assess the effect of tusamitamab ravtansine (i.e., change from baseline) on cardiac parameters such as QT interval corrected according to the Bazett's formula (QTcB).	Baseline, Cycle 1, and Cycle 2 (1 Cycle = 2 weeks)
Secondary	ECG parameter: QRS interval	To assess the effect of tusamitamab ravtansine (i.e., change from baseline) on cardiac parameters such as QRS interval.	Baseline, Cycle 1, and Cycle 2 (1 Cycle = 2 weeks)
Secondary	ECG parameter: PR interval	To assess the effect of tusamitamab ravtansine (i.e., change from baseline) on cardiac parameters such as PR interval.	Baseline, Cycle 1, and Cycle 2 (1 Cycle = 2 weeks)
Secondary	Maximum concentration observed (Cmax)		Multiple timepoint at Cycle 1 (1 Cycle = 2 weeks)
Secondary	Area under the plasma concentration versus time curve from time 0 to 14 days (AUC0-14d)		Multiple timepoint at Cycle 1 (1 Cycle = 2 weeks)
Secondary	Incidence of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and laboratory abnormalities	Assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.	From the date of first infusion up to approximately 30 days after the last infusion i.e., up approximately 34 weeks
Secondary	Overall response rate (ORR)	The ORR, defined as the proportion of participants who have a confirmed complete response (CR) or partial response (PR) as the best overall response as determined by investigator/local radiologist review per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria	Up to approximately 30 weeks
Secondary	Duration of response (DOR)	The DOR, defined as the time from the first documented evidence of confirmed complete response (CR) or partial response (PR) until progressive disease (PD) as determined by investigator/local radiologist review per RECIST v1.1 criteria or death (due to any cause), whichever comes first	Up to approximately 30 weeks